<h4>Objectives</h4>The objective of anti-VEGF (Vascular Endothelial Growth Factor) injections in the treatment of central serous chorioretinopathy (CSCR) is to help reduce fluid accumulation beneath the retina, promote resolution of retinal edema, and potentially prevent complications like permanent vision loss.The goal is to stabilize or improve vision by improving visual outcomes by reducing fluid and promoting retina reattachment.<h4>Case presentation</h4>A 43-year-old Caucasian male presented with painless, decreased vision in the left eye. This evidence concerns the gene VEGFA and central serous retinopathy.